US Food and Drug Administration Approves FoundationOne^®CDx as a Companion Diagnostic for TEPMETKO^® (tepotinib) to Identify Patients with MET Exon 14 Skipping Alterations in Non-Small Cell Lung Cancer

Foundation Medicine, Inc., announced that it has received approval from the US FDA for FoundationOne^®CDx to be used as a companion diagnostic (CDx) for TEPMETKO^® (tepotinib) developed by EMD Serono, the healthcare business of Merck KGaA, Darmstadt, Germany in the US and Canada.